BUX-4/UCA UC

PI: Doron Schwarz. Funded: TCA

Phase II UC

 PI: Doron Schwarz. Funded: Cato

TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness.

PI: Ohad Etzion. Funded: Accelsiors

Microbiome.

PI: Naim Abu-Freha. Funded: Biotax

AMT-101-205.

PI: Doron Schwarz

Janssen Research & Development IBD clinical studies.

PI: Doron Schwarz

GSK 212260.

PI: Ohad Etzion. Funded: Janssen

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065.

PI: Arik Segal. Funded: AbbVie

PHASE 2A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF CM-101 IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH).

PI: Ohad Etzion, ChemomAb Ltd.

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects with Primary Sclerosing Cholangitis.

PI: Ana Nevo Shor. Funded: ChemomAb Ltd.

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR).

PI: Ohad Etzion. Funded: Eiger BioPharmaceuticals, Inc

I Cure C.

PI: Ohad Etzion. Funded: Collaboration with Ichilov

AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144.

PI: Doron Schwarz. Funded: IQVIA

Introduction of culture- based assay for H. Pylori resistance testing.

PI: Daniela Munteanu

A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease

PI: Doron Schwarz. Funded: Parexel

A two-part, randomized, placebo controlled, double blind, multicenter, Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (PBC).

PI: Ohad Etzion

GSK 212260

PI: Ohad Etzion

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease. I6T-MC-AMAM. Genetic part.

PI: Arik Segal. Funded: Eli Lilly

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants With Moderately to Severely Active Crohn's Disease.

PI: Doron Schwarz. Funded: Parexel

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis (genetic part).

PI: Aviel Hadad. Funded: IQVIA

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis (genetic part)

PI: Arik Segal. Funded: Eli Lilly

A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

PI: Ohad Etzion. Funded: Madrigal Pharmaceuticals, Inc

Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn’s Disease.

PI: Arik Segal. Funded: Mapi S.A.S

A randomised, double-blind, placebo-controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver biopsy.

PI: Ohad Etzion. Funded: INVENTIVA S.A.

Entyvio PASS Study

PI: Doron Schwarz. Funded: Praxell

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

PI: Doron Schwarz. Funded: Praxell

Combined Phase 3, Double-blind, Randomized, Placebo Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease

PI: Doron Schwarz. Funded: PRA

A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease

PI: Doron Schwarz. Funded: PRA

A Phase 3b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cirrhosis

PI: Ohad Etzion. Funded: Syneos Health Clinical Ltd.

EVALUATION OF C-SCAN IN IDENTIFYING SUBJECTS WITH ELEVATED RISK OF COLON POLYPS

PI: Naim Abu-Freha. Funded: Check-Cap ltd

A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

PI: Ohad Etzion. Funded: Can Fite Biopharma

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis

PI: Ohad Etzion. Funded: Covance

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991.

PI: Arik Segal. Funded: AbbVie

M20-371: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD): AIM-CD

PI: Arik Segal. Funded: AbbVie

Prospective real-world study of upadacitinib in ulcerative colitis (PROFUNDUS)

PI: Arik Segal. Funded: AbbVie

A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects with Ulcerative Colitis (UC)

PI: Doron Schwarz. Funded: AbbVie

A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled Study toEvaluatethe Safety, Efficacy, and Pharmacokinetics of InductionTherapy with PRA023 in Subjects with ModeratelytoSeverely Active Ulcerative Colitis

PI: Doron Schwarz. Funded: Alimentiv

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease

PI: Arik Segal. Funded: Eli Lilly

Identification of epitopes stimulating the immune system in patients with suspected celiac disease

PI: Hiba Abu-Kaf. Funded: Ukko

A multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF)

PI: Hiba Abu-Kaf. Funded: PSI

Maintenance Treatment of Subcutaneous Vedolizumab for Inflammatory Bowel Disease. An Observational Study.

PI: Doron Schwarz. Funded: Takeda

A Phase 2a, randomized, double-blind, placebo-controlled, crossover, multicenter study to evaluate the safety, tolerability and efficacy of Cannabidiol (CBD) as a steroid-sparing therapy in steroid-dependent Crohn’s Disease patients

PI: Doron Schwarz. Funded: STERO

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis (NASH)

PI: Ohad Etzion. Funded: Covance, Intercept Clinical Study 747-303

A Phase 3, Randomized, Open-Label, Parallel Arm Study to Evaluate the Efficacy and Safety of 180 mcg Peginterferon Lambda-1a (Lambda) Subcutaneous Injection for 48 Weeks in Patients with Chronic Hepatitis Delta Virus (HDV) Infection (LIMT-2)

PI: Ohad Etzion. Funded: Eiger BioPharmaceuticals, Inc

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease

PI: Arik Segal. Funded: Eli Lilly

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Biologic Therapy.

PI: Doron Schwarz. Funded: AbbVie

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or are Intolerant to Conventional Therapies but Have Not Failed Biologic Therapy.

PI: Doron Schwarz. Funded: AbbVie

A Multicenter, Randomized, Double Blind, Placebo Controlled Maintenance and Long Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT 494) in Subjects with Crohn’s Disease who Completed the M14-431 or M14-433 Studies.

PI: Doron Schwarz. Funded: AbbVie

Enema treatment for UC

PI: Doron Schwarz. Funded: STERO

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate-to-Severe Crohn's Disease

PI: Doron Schwarz. Funded: PRA

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate-to-Severe Crohn's Disease

PI: Doron Schwarz. Funded: PRA

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate-to-Severe Crohn's Disease

PI: Doron Schwarz. Funded: PRA

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis.-LUCENT

PI: Arik Segal. Funded: Eli Lilly

Randomised, double-blind, placebo-controlled study of the, efficacy, safety and tolerability of EPA-FFA gastro-resistant capsules, in patients with familial adenomatous polyposis (FAP)

PI: Naim Abu-Freha. Funded: S.L.A Pharma UK Ltd.

An Adaptive Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3471851 (NKTR-358) in Patients with Moderately to Severely Active Ulcerative Colitis.

PI: Arik Segal. Funded: Eli Lilly

Once Daily (QD) Dosing of Lonafarnib (LNF) Co-administered with Ritonavir (RTV) for Treatment of Chronic Hepatitis D Virus Infection

PI: Ohad Etzion. Funded: Eiger BioPharmaceuticals, Inc

Crohn’s Disease

PI: Doron Schwarz. Funded: Q-trials

Crohn’s Disease

PI: Doron Schwarz. Funded: PSI

Takeda SPOTLITE

PI: Arik Segal. Funded: IQVIA

TA799-012

PI: Hiba Abu-Kaf. Funded: PSI

site -LIMIT 2

PI: Ohad Etzion. Funded: BIORASI

EP547 PBC

PI: Ohad Etzion. Funded: Escient Pharmaceuticals, Inc

Circulating micro-RNA (miR) and iso-miR profiling for cardiometabolic risk stratification in patients with non-alcoholic fatty liver disease (NAFLD)

PI: Ohad Etzion. Funded: Grant

Treatment withdrawal in HBeAg-negative chronic hepatitis B patients: a prospective study aiming to retrospectively assess the predictive value of new serological markers

PI: Ohad Etzion